U.S. markets close in 4 hours 6 minutes

Spire Inc. (SR)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
75.59+0.29 (+0.39%)
As of 11:37AM EDT. Market open.
Sign in to post a message.
  • I
    Ice G
    Hoping for some news on Sorrento in the coming days. Taken from NY Post article today “We’re hopeful that, with some of the breakthrough technology on therapeutics, that we will be able to announce some new therapies in the coming days,” Meadows said in an interview with ABC News.

    https://nypost.com/2020/07/26/new-covid-19-treatments-may-be-days-away-wh-chief-of-staff/
    White House Chief of Staff Mark Meadows on Sunday said he was “hopeful” that within days there will be an announcement on new treatments for COVID-19. “We’re hopeful that, w…
    White House Chief of Staff Mark Meadows on Sunday said he was “hopeful” that within days there will be an announcement on new treatments for COVID-19. “We’re hopeful that, w…
    nypost.com
    Bullish
  • Y
    Your Daddy
    Bought some shares of Spire at $60.50 the other day. Very low PE ratio and a nice dividend. I think this has a lot of upward mobility and will provide some nice cashflow to boot.
  • T
    Tom
    I bought this stock in May 2012 for around $38/share when it was known as LeClede Gas. My dividend is inching up near 6%. Every year like clockwork, they have raised the dividend. Unless something drastic happens with this company, I'll probably be holding this until I die.
  • Y
    Yahoo Finance Insights
    SR reached a new 52 Week Low at 61.00
  • h
    halfaker
    Hello there. The markets are shaky right now and a crash could be imminent. Do you know where to put your cash? go to (http://Multistockalerts.com)
  • Y
    Yahoo Finance Insights
    SR-PA reached an all time low at 24.80
  • s
    steve
    I'm new to this stock. Where is the bottom? I'm going to buy once it hits as low as it can be. Is there a traditional season where the stock is high? nice divys..
  • Y
    Yahoo Finance Insights
    Spire is up 4.99% to 71.37
  • M
    Meltdown
    Another D44 summary of the Sorrento programs ....

    "Look for one PR followed by another elevating Sorrento shares to new successive highs in the next several months.
    Not only are investors awaiting EUA approval of it's COVIDTRACK test kit for the independent detection of IgG and IgM antibodies in sera of patients exposed to the SARS-CoV-2 virus. Investors are also waiting on positive news for approval of their antibody cocktail "COVI-SHIELD" STI-1499..the company's preventative treatment.

    NIH Clinical trial listing posted 6/25 & 7/1 waiting for FDA approvals to initiate..

    NEW
    Not yet recruiting
    Study to Evaluate STI-1499 (COVI-GUARD) in Hospitalized Patients With COVID-19

    Condition
    Covid-19
    Interventions:
    Biological: STI-1499
    Other: Standard of Care
    Drug: Placebo
    Locations:

    NEW
    Not yet recruiting
    Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19

    Condition
    Covid-19
    Interventions:
    Drug: Abivertinib
    Other: Standard of Care
    Locations:

    Longer term..

    The future of Sorrento lies in it's core Oncology & Pain programmes. Core programs listed in order of importance to the company. COVID is the most recent addition to the company's platforms. As you can see below from Sorrento's extensive research.. cancer & pain
    are core to the company's
    programmes..

    Immuno-Oncology
    Key Programs

    *CART (MultipleMyeloma)
    Ph I

    *CD38 DAR-T (Multiple Myeloma)
    Preclinical

    *CD38 ADC (Amyloidosis)
    Ph I

    *Seprehvir™ (Solid Tumors)
    Ph I

    Pain Key Programs

    *RTX (resiniferatoxin) Epidural route (Terminal Cancer Pain)
    Ph II

    *RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA)
    Ph II

    *RTX (resiniferatoxin) Intra-articular route
    (TKR Deferment)
    Preclinical

    Lymphatic DeliveryKey Programs

    *Sofusa® anti-TNF (Autoimmune)
    Preclinical

    *Sofusa® anti-PD-1
    (ImmunoOncolog)
    Preclinical

    COVID-19 Programs
    Key Programs

    *COVIDGUARD
    Preclinical

    *COVIDSHIELD
    Preclinical

    *COVIDTRAP
    Preclinical

    Sorrento's many Partnerships & Subsidiaries

    SCILEX
    58% ownership stake.
    IPO pending 2020

    BIOSERV
    100% owned subsidiary.

    CONCORTIS/ LEVENA 100% owned subsidiary

    ARK ANIMAL HEALTH
    100% owned subsidiary

    YUHAN
    35% ownership of ImmuneOncia JV

    LEE PHARM
    Sorrento licensee. Collaboration

    CELULARITY
    25% ownership stake
    JDA ( joint development agreement) $5 ml

    MABPHARM
    Collaboration & development

    https://sorrentotherapeutics.com/partnership/
    Partner: Asset Type: Partner Background: Partnership Details: Partner: Asset Type: Immuno-Oncology Partner Background: Yuhan Corporation is one of the largest Korean pharmaceutical companies, founded over 80 years ago Partnership Details: Joint Ventu
    Partner: Asset Type: Partner Background: Partnership Details: Partner: Asset Type: Immuno-Oncology Partner Background: Yuhan Corporation is one of the largest Korean pharmaceutical companies, founded over 80 years ago Partnership Details: Joint Ventu
    sorrentotherapeutics.com
  • R
    Ron
    $SR will provide an update on its growth initiatives as well as recent performance and developments. Here is the link for more info http://crweworld.com/article/news-provided-by-pr-newswire/303039/spire-to-present-at-aga-financial-forum
  • N
    Nermin
    $TNP conversation
    Most significant #oil #tanker spot movements today:

    #VLCC -7% to $57k/d
    #Aframax +13% to $43k/d
    #LR2 -14% to $15.6k/d
    #SR -25% to $18.0k/d
  • N
    Nermin
    $TNP conversation
    Most significant #oil #tanker spot movements today:

    #VLCC -7% to $57k/d
    #Aframax +13% to $43k/d
    #LR2 -14% to $15.6k/d
    #SR -25% to $18.0k/d
  • p
    priit
    $FRO conversation
    #VLCC -31% to $20k/d
    #Aframax -20% to $5.0k/d
    #SR +33% to $5.1k/d
  • s
    stocktargetadvisor
    $SR
    Target Raised by Morgan Stanley Equal Weight USD 68 » USD 69
    Target Lowered by Credit Suisse Outperform USD 71 » USD 69
  • E
    Eric
    I told you that please don't post anything until we have some good news.
  • Y
    Yahoo Finance Insights
    SR-PA reached an all time low at 25.25
  • Y
    Yahoo Finance Insights
    SR-PA reached an all time low at 25.14
  • Y
    Yahoo Finance Insights
    SR-PA reached an all time low at 25.35
  • Y
    Yahoo Finance Insights
    SR-PA reached an all time low at 26.61